Alterity Therapeutics Ltd ADR (ATHE) concluded trading on Thursday at a closing price of $4.57, with 22.97 million shares of worth about $104.96 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 183.85% during that period and on January 30, 2025 the price saw a gain of about 57.04%. Currently the company’s common shares owned by public are about 8.74M shares, out of which, 8.45M shares are available for trading.
Stock saw a price change of 30.95% in past 5 days and over the past one month there was a price change of 86.53%. Year-to-date (YTD), ATHE shares are showing a performance of 38.07% which increased to 147.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.00 but also hit the highest price of $4.71 during that period. The average intraday trading volume for Alterity Therapeutics Ltd ADR shares is 70.82K. The stock is currently trading 31.11% above its 20-day simple moving average (SMA20), while that difference is up 85.77% for SMA50 and it goes to 148.33% higher than SMA200.
Alterity Therapeutics Ltd ADR (NASDAQ: ATHE) currently have 8.74M outstanding shares and institutions hold larger chunk of about 1.36% of that.
The stock has a current market capitalization of $40.54M and its 3Y-monthly beta is at 0.65. It has posted earnings per share of -$2.06 in the same period. It has Quick Ratio of 3.54 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATHE, volatility over the week remained 18.74% while standing at 16.16% over the month.
Stock’s fiscal year EPS is expected to rise by 50.35% while it is estimated to increase by 24.69% in next year. EPS is likely to grow at an annualized rate of 29.75% for next 5-years, compared to annual growth of 24.86% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on December 12, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
